OTC Markets OTCPK - Delayed Quote USD

Innovent Biologics, Inc. (IVBXF)

5.97

0.00

(0.00%)

At close: April 22 at 4:00:00 PM EDT

High Growth Tech Stocks In Asia For April 2025

As trade tensions between the U.S. and China escalate, investor sentiment in global markets has been volatile, with key indices like the Nasdaq Composite experiencing significant fluctuations. Despite these challenges, Asia's tech sector continues to attract attention for its potential high growth opportunities, especially as companies in this region seek to innovate and expand amidst a shifting economic landscape. In such an environment, identifying stocks that demonstrate resilience and...

Simply Wall St. 8 days ago

IVBIY

IVBXF
0.00%
XIACF
3 Asian Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.6%

Amidst growing global trade concerns and economic uncertainty fueled by recent tariff announcements, Asian markets have faced significant volatility, reflecting broader apprehensions about potential impacts on growth and inflation. In this environment, identifying stocks that are trading below their intrinsic value can offer investors opportunities to potentially capitalize on market mispricing.

Simply Wall St. 16 days ago

IVBIY

IVBXF
0.00%
6990.HK
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibo

PR Newswire 23 days ago

IVBIY

IVBXF
0.00%
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Me

PR Newswire 27 days ago

IVBIY

IVBXF
0.00%
Innovent Announces 2024 Annual Results and Business Updates

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2024 annual results, including major business updates, financial performance and the strategy and outlook for 2025 and beyond.

PR Newswire 27 days ago

IVBIY

IVBXF
0.00%
Innovent Biologics doses first subject in trial of ovarian cancer therapy

The trial aims to assess the ADC’s efficacy and safety against the investigator's choice of chemotherapy.

Clinical Trials Arena 29 days ago

IVBIY
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) in a randomized, controlled, multicenter Phase 3 clinical trial (HeriCare-Ov

PR Newswire 30 days ago

IVBIY

IVBXF
0.00%
Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trial

The companies received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Clinical Trials Arena last month

GLDAF

IVBIY
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the FRUSICA-2 Phase 2/3 clinical trial evaluating sintilimab in combination with fruquintinib as second-line treatment for loca

PR Newswire last month

IVBIY

IVBXF
0.00%
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China has met its primary endpoint of progression free survival (“PFS”) per RE

GlobeNewswire last month

HCM

HMDCF

IVBIY
High Growth Tech Stocks In Asia To Watch March 2025

As global markets grapple with inflation concerns and trade policy uncertainties, Asian tech stocks are capturing attention amid shifting economic dynamics. In this environment, identifying high-growth opportunities requires a focus on companies that demonstrate resilience and adaptability to evolving market conditions.

Simply Wall St. last month

IVBIY

IVBXF
0.00%
China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SYCUME® (teprotumumab N01, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody) for the treatment of thyroid eye di

PR Newswire last month

IVBIY

IVBXF
0.00%
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in its registrational study evaluating IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, as monotherapy versus pembrolizumab (Keytruda®) in patient

PR Newswire last month

IVBIY

IVBXF
0.00%
NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for ipilimumab injection (anti-CTLA-4 monoclonal antibody; R&D Code: IBI310) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Admini

PR Newswire last month

IVBIY

IVBXF
0.00%
Q Technology (Group) And 2 More Stocks That May Be Trading Below Estimated Value

As global markets continue to navigate the complexities of rising inflation and monetary policy adjustments, U.S. stock indexes are climbing towards record highs, buoyed by investor optimism and strategic economic decisions. In this environment, identifying undervalued stocks can be a prudent strategy for investors seeking potential opportunities amidst market fluctuations. Evaluating factors such as strong fundamentals and growth prospects can help in recognizing stocks that may be trading...

Simply Wall St. last month

IVBIY

IVBXF
0.00%
LNVGF
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies

PR Newswire 2 months ago

IVBIY

IVBXF
0.00%
Exploring High Growth Tech And 2 Other Prominent Stocks With Potential

Amidst a backdrop of fluctuating global markets, the U.S. technology sector has faced notable volatility, driven by competitive pressures in artificial intelligence and mixed corporate earnings reports. As investors navigate these challenges, identifying high-growth tech stocks with strong fundamentals and resilience to market shifts can be crucial for capitalizing on potential opportunities in this dynamic environment.

Simply Wall St. 2 months ago

IVBIY

IVBXF
0.00%
CDE grants BTD to Innovent’s IBI343 for pancreatic cancer

The BTD is supported by the data from an ongoing Phase I trial.

Pharmaceutical Technology 3 months ago

IVBIY
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), jointly announce that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the treatmen

PR Newswire 3 months ago

IVBIY

IVBXF
0.00%
Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, participated in the 43rd Annual J.P. Morgan Healthcare Conference.

PR Newswire 3 months ago

IVBIY

IVBXF
0.00%

Performance Overview

Return	IVBXF	HANG SENG INDEX (^HSI)
YTD	+25.84%	+10.03%
1-Year	+37.36%	+31.16%
3-Year	+95.90%	+6.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innovent Biologics, Inc. (IVBXF)

High Growth Tech Stocks In Asia For April 2025

3 Asian Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.6%

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting

Innovent Announces 2024 Annual Results and Business Updates

Innovent Biologics doses first subject in trial of ovarian cancer therapy

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trial

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

High Growth Tech Stocks In Asia To Watch March 2025

China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer

Q Technology (Group) And 2 More Stocks That May Be Trading Below Estimated Value

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

Exploring High Growth Tech And 2 Other Prominent Stocks With Potential

CDE grants BTD to Innovent’s IBI343 for pancreatic cancer

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Performance Overview